Heritage Cannabis Holdings Corp. (CSE:CANN;OTC:HERTF) (“Heritage” or “Company”) is pleased to announce that it has entered into a binding term sheet effective May 8th, 2019 (the “Term Sheet”) that will form the basis for a Mutual Supply Agreement and a Services Agreement (the “Agreements”) with Zenabis Global Inc. (“Zenabis”) which will see the two companies work collaboratively together for the shared benefit of both organizations.

The Term Sheet calls for Heritage, via its wholly owned subsidiary Purefarma Solutions Inc. (“Purefarma”) to provide both toll extraction services and various formulated extracted oil products to Zenabis. Additionally, the Term Sheet will have Zenabis supplying Heritage with dried flower and trim for extraction. This arrangement extends to both British Columbia and Ontario for extraction services, while Zenabis will supply the cannabis product from each of their facilities in New Brunswick, Nova Scotia and British Columbia.


Furthermore, this open-ended Term Sheet includes option for both Heritage and Zenabis to jointly pursue the co-development of formulated CBD distillate, CBD isolate, Liquid oil THC distillate and THC and CBD concentrates. Scientists from Zenabis will look to collaborate with Heritage’s medical sciences division to create a series of specialized products which would be marketed directly through various online portals with the intent for those products with regulatory approval being available to the public by summer 2019.

“This is a great opportunity to leverage the strengths of Zenabis and Heritage for the mutual benefit of both companies.” states Andrew Grieve, CEO of Zenabis “We look forward to creating something special to bring to the market.”

The initial Agreements will see Zenabis deliver a minimum of 500 kg of dried flower and trim to Heritage, and in return Heritage will supply Zenabis with a minimum of 150 kg of CBD or THC extracted distillate, both to be delivered by the end of 2019.

“We are excited to be working with Zenabis in this unique approach. Both companies are projecting significant growth, and this agreement is designed to be scalable to address future needs.” says Clint Sharples, CEO of Heritage. “We are off to a strong start in 2019 and have been working diligently to ramp up our capacity to support industry growth.”

About Zenabis Global Ltd

Zenabis is a Canadian publicly listed licensed cultivator of medical and recreational cannabis. The company was formed in January, 2019, through the combination of Bevo Agro Inc., one of the largest propagation businesses in North America, and Sun Pharm Investments Ltd., a large privately held licensed cannabis producer with established medical and recreational cannabis brands and distribution. The company owns six state-of-the-art indoor and greenhouse facilities across Canada, four of which are intended for cannabis cultivation. If all four such facilities are fully built out and converted to cannabis production, they would have a design capacity to yield approximately 479,300 kilograms of dried cannabis annually.

About Heritage Cannabis Holdings Corp.

The Company is focused on becoming a vertically integrated cannabis provider that currently has two Health Canada approved licenced producers, through its subsidiaries Voyage Cannabis Corp. and CannaCure Corp. both regulated under the Cannabis Act Regulations. Working under these two licences, Heritage has two additional subsidiaries, Purefarma Solutions, which provides extraction services, and BriteLife Sciences which is focused on cannabis based medical solutions. Heritage as the parent company, is focused on providing the resources for its subsidiaries to advance their products or services to compete both domestically and internationally.

ON BEHALF OF THE BOARD OF DIRECTORS OF HERITAGE CANNABIS HOLDINGS CORP.

“Clint Sharples”

Clint Sharples

CEO

For more information contact:

Clint Sharples

Tel: 416-705-8529

csharples@heritagecann.com

or

Elizabeth Thomas

Tel: 905-321-8086

ethomas@heritagecann.com

The Canadian Stock Exchange does not accept responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors – including the availability of funds, the results of financing efforts, the results of exploration activities — that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Click here to connect with Heritage Cannabis Holdings Corp. (CSE:CANN;OTC:HERTF) for an Investor Presentation. 

Source: www.thenewswire.com

NYSE | TSX: ACB

Aurora Cannabis Inc. (“Aurora” or the “Company”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today has announced today that it has entered into an agreement with a syndicate of underwriters led by BMO Capital Markets and ATB Capital Markets, under which the underwriters have agreed to buy on bought deal basis 12,000,000 units of the Company (the “Units”), at a price of US$10.45 per Unit for gross proceeds of approximately US$125 million (the “Offering”). Each Unit will be comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant will be exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less

Trading resumes in:

Company: Revive Therapeutics Ltd.

Keep reading... Show less

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES /

Revive Therapeutics Ltd. (” Revive ” or the ” Company “) (CSE:RVV) ( USA : RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into an amended agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (collectively, the ” Underwriters “), to increase the size of its previously announced offering of units (the ” Equity Units “) at a price of $0.50 per Equity Unit. Under the amended terms, the Underwriters have agreed to purchase, on a bought deal basis, 40,000,000 Equity Units for gross proceeds to the Company of $20,000,000 (the ” Offering “). The over-allotment option granted to the Underwriters will proportionately increase to 15% of the Offering.

Keep reading... Show less

The new dispensary brings expanded access for patients in the growing communities of Central Florida

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 77th nationwide. The new, 5,100 sq. ft. location marks the Company’s first in Summerfield expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”).

The Company announced today that its board of directors have approved a private placement of up to 15,000,000 units at a price of $.40 per unit for gross proceeds of up to $6,000,000. Each unit will consist of one common share of the Company and one share purchase warrant. Each share purchase warrant will be exercisable to purchase an additional common share at a fixed price of $.45 per share for a period of one year from closing.

Keep reading... Show less